UK, July 2011 – Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin’s GMP quality Pluripotent Stem Cells (PSC).
The evaluation will allow Pfizer access to Roslin’s cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin’s GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Aidan Courtney, Roslin Cells CEO commented ‘We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are already being used in our own collaborative research programmes and I am delighted that they will now be evaluated for potential use by Pfizer.’
Commercial terms are confidential and not disclosed.
About Roslin Cells
Roslin Cells Ltd was established as an independent company by Roslin Institute in 2006 with the aim of providing ethically sourced, pluripotent human cells manufactured to the highest quality available according to Good Manufacturing Practice (GMP standards). This level of quality is critical to their intended use in therapeutic applications. The Company now also assists academic and commercial researcher organisations to translate fundamental research into GMP compliant processes which can be used in the production of cell therapies. In October 2010 the Company announced its Cell Therapy Partner Program through which it helps the development of new cell therapies.
Roslin Cells is headquartered near Edinburgh, Scotland, and is a not for profit organisation. Further information can be found atwww.roslincells.com.
For further Information
Roslin Cells Ltd
Chief Executive Officer
Tel +44 131 527 4243
Fax +44 131 527 4517